Mononeuritis multiplex as a rare and severe neurological complication of immune checkpoint inhibitors: a case report
Abdelhakim S, Klapholz JD, Roy B, Weiss SA, McGuone D, Corbin ZA. Mononeuritis multiplex as a rare and severe neurological complication of immune checkpoint inhibitors: a case report. Journal Of Medical Case Reports 2022, 16: 81. PMID: 35197122, PMCID: PMC8867751, DOI: 10.1186/s13256-022-03290-1.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overFemaleHumansImmune Checkpoint InhibitorsIpilimumabMononeuropathiesNeoplasm Recurrence, LocalNervous System DiseasesConceptsImmune checkpoint inhibitorsMononeuritis multiplexCheckpoint inhibitorsCell death protein 1/Cytotoxic T-lymphocyte antigen-4Death ligand 1 (PD-L1) axisDeath protein 1/Immune checkpoint inhibitor therapyT-lymphocyte antigen-4Progressive leg weaknessCheckpoint inhibitor therapyProgressive neurologic dysfunctionSevere neurological complicationsAutoimmune peripheral neuropathyNon-Hispanic white femalesSevere side effectsLigand-1 axisChronic steroidsCombination ipilimumabConclusionsIncreased awarenessIntravenous immunoglobulinNeurological complicationsParaneoplastic syndromeAggressive treatmentInhibitor therapy